Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma
Authors Luo J, Cao C, Zhu Y, Liu P, Liu L, Lu K, Zhang N, Zhou N
Received 19 June 2016
Accepted for publication 23 August 2016
Published 11 October 2016 Volume 2016:9 Pages 6147—6150
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 3
Editor who approved publication: Dr Samir Farghaly
Jialin Luo,* Caineng Cao,* Yuan Zhu, Peng Liu, Luying Liu, Ke Lu, Na Zhang, Ning Zhou
Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, People’s Republic of China
*These authors contributed equally to this work
Background and objective: The objective of the study was to evaluate the efficiency of chemotherapy (CT) combined with high-dose extended-field radiotherapy (RT) in stage I extranodal nasal-type natural killer/T-cell lymphoma (NKTCL).
Patients and methods: Between January 2001 and November 2010, 103 stage I extranodal nasal-type NKTCL patients were retrospectively analyzed. Of these patients, 75 patients were treated by RT plus CT and 28 patients were treated by RT alone. CT included cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or CHOP-like regimen.
Results: The median follow-up time was 42.6 months (range, 7.4–126.7 months). For patients in the RT alone group, the 5-year estimated progression-free survival (PFS) and overall survival (OS) rates were 67.0% and 71.4%, respectively. For patients in the RT + CT group, the 5-year estimated PFS and OS rates were 69.0% and 63.7%, respectively. In multivariate analysis, CT was an independent factor for PFS.
Conclusion: The doxorubicin-based CT combined with high-dose extended-field RT yielded promising outcomes for stage I extranodal nasal-type NKTCL, and CT was an independent factor for PFS.
Keywords: natural killer/T-cell lymphoma, chemotherapy, radiotherapy, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]